Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
The upcoming earnings report for APLS is scheduled for Tuesday, May 5th, with a consensus estimate of -0.38 EPS.
Apellis Pharmaceuticals, Inc. is currently priced at $40.95, reflecting a slight decrease of -0.5 cents (-0.012%) from the previous close. Trading volume is at $1.31 million, representing a 25.32% increase.
The latest quarterly earnings for APLS were reported on Monday, February 23rd, with a consensus estimate of -0.39 EPS.
The company experienced a net change in cash of -$12.84 million, with operating cash flow at -$14.18 million. Cash at the end of the period stands at $467.76 million.
APLS generated $199.91 million in revenue, resulting in a gross profit of $170.19 million. The company reported a net income of -$58.95 million, translating to an EPS of -47 cents.
Key ratios include a quick ratio of 2.7, gross profit margin of 85.13%, and a debt-equity ratio of 131.38.
Total assets amount to $1 billion, with total liabilities at $705.11 million. Cash and cash equivalents stand at $467.76 million.
This article provides an overview of APLS's current financial status, upcoming earnings, performance analysis, and key financial metrics.